ReviewFrontiers in pharmacology2021
Deep Eutectic Solvents as Active Pharmaceutical Ingredient Delivery Systems in the Treatment of Metabolic Related Diseases.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- The Effect ofNutrients · 2022Pooled it
- Computational screening of natural deep eutectic solvents for improving naringenin solubilization and membrane behavior in DMPC liposomes Using COSMO-RS and COSMOmic.Journal of molecular modeling · 2026Article
- A Comparative Study on Mechanochemically and Thermally Prepared Deep Eutectic Solvents.ACS omega · 2025Article
- The Role of Natural Deep Eutectic Solvents in a Hydrogel Formulation Containing Lidocaine.Pharmaceutics · 2025Article
- The high potential of methyl laurate as a recyclable competitor to conventional toxic solvents in [3 + 2] cycloaddition reactions.Beilstein journal of organic chemistry · 2025Article
- Conformational Geometry Matters: The Case of the Low-Melting-Point Systems of Tetrabutylammonium Triflate with Fumaric or Maleic Acid.Molecules (Basel, Switzerland) · 2024Article
- Exploring Deep Eutectic Solvents as Pharmaceutical Excipients: Enhancing the Solubility of Ibuprofen and Mefenamic Acid.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Pharmaceutical applications of therapeutic deep eutectic systems (THEDES) in maximising drug delivery.Heliyon · 2024Review
- Deep Eutectic Solvents Comprising Organic Acids and Their Application in (Bio)Medicine.International journal of molecular sciences · 2023Review
- Challenging DESs and ILs in the valorization of food waste: a case study.Frontiers in chemistry · 2023Article
- Bibliometric analysis and visualization of transdermal drug delivery research in the last decade: global research trends and hotspots.Frontiers in pharmacology · 2023Article
- Therapeutic deep eutectic solvent-based microemulsion enhances anti-inflammatory efficacy of curcuminoids and aromatic-turmerone extracted fromRSC advances · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic related diseases such as cancer, diabetes mellitus and atherosclerosis are major challenges for human health and safety worldwide due to their associations with high morbidity and mortality. It is of great significance to develop the effective active pharmaceutical ingredient (API) delivery systems for treatment of metabolic diseases. With their unique merits like easy preparation, high adjustability, low toxicity, low cost, satisfactory stability and biodegradation, deep eutectic solvents (DESs) are unarguably green and sustainable API delivery systems that have been developed to improve drug solubility and treat metabolic related diseases including cancer, diabetes mellitus and atherosclerosis. Many reports about DESs as API delivery systems in the therapy of cancer, diabetes mellitus and atherosclerosis exist but no systematic overview of these results is available, which motivated the current work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.